

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

François HIRSCH et al.

Box PCT

Serial No. (unknown)

Application Branch

Filed herewith

NF- $\kappa$ B ACTIVATION  
INHIBITORS, AND THEIR  
PHARMACEUTICAL USES

PRELIMINARY AMENDMENT

Commissioner for Patents

Washington, D.C. 20231

Sir:

Prior to the first Official Action and calculation of the filing fee, please amend the above-identified application as follows:

IN THE CLAIMS:

Amend claim 3 as follows:

--3. (amended) The use according to claim 1, of compounds inhibiting the activation of NF- $\kappa$ B connected specifically to the transmembranal receptors of the cytokins of class I in the cells of the organism, such as compounds selected from growth hormone or erythropoietin.--

Amend claim 4 as follows:

--4. (amended) The use according to claim 1:  
- of the human growth hormone, as obtained by extraction from hypophysary extracts, and purification,